Data Assets & Alpha Group: Demystifying AI in the Financial Domain (Part 2)
In this 2-part episode, we delve into 5 major AI / ML models and 40+ associated keywords, running through the merits and differences between those models, the drawbacks from each, and use cases in app...
15 Joulu 202327min
2024 Outlook: Windows of Opportunity, Bouts of Volatility
In this year-end episode, host Kathleen Darling leads a roundtable discussion with Kevin Foley, Global Head of Debt Capital Markets, and Achintya Mangla, Global Head of Equity Capital Markets. Dive in...
14 Joulu 202323min
Data Assets & Alpha Group: Demystifying AI in the Financial Domain (Part 1)
In this 2-part episode, we delve into 5 major AI / ML models and 40+ associated keywords, running through the merits and differences between those models, the drawbacks from each, and use cases in app...
13 Joulu 202327min
FICC Market Structure: Breaking Down Basel III: What the US Proposals Could Mean
What is Basel III and how might the recent US proposals impact markets? Kate Finlayson, Global Head of FICC Market Structure, and Meridy Cleary in FICC Market Structure, break down the key considerati...
11 Joulu 202310min
Does the November Jobs Report Point to a Soft Landing?
In November, the U.S. economy added 199,000 jobs — boosted by workers returning from strikes — while the unemployment rate fell to 3.7%. What does this all mean for the Fed’s soft landing narrative? J...
8 Joulu 20234min
2024 Investment Banking Outlook
As we wrap up 2023, David Rawlings hosts Jay Horine, North America Head of Investment Banking and Co-Head of Global Energy, Power, Renewables and Mining, for a conversation about what’s ahead for inve...
7 Joulu 202317min
Why is Cybersecurity in the Spotlight?
Recent high-profile data breaches and geopolitically motivated cyber-attacks are driving awareness around the importance of risk mitigation. What’s the overall health of the cybersecurity sector? Will...
4 Joulu 202321min
The Growing Appetite for Obesity Drugs
The market for GLP-1s — also commonly known as obesity drugs — is projected to exceed $100 bn globally by 2030. Why are these drugs growing in popularity, and could they lead to a paradigm shift in he...
1 Joulu 202324min
